Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTAF trial of Xeomin for prevention of postoperative atrial fibrillation after cardiac surgery
2024-513645-37-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Xeomin with Placebo (2 arms). Primary endpoint: Incidence of postoperative atrial fibrillation or atrial arrhythmia within 21 days after cardiac surgery. Started Sep 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2024-513645-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513645-37-00.